Research & Education

CAP/IASLC/AMP Molecular Testing Guideline: Open Comment Period

Public Open Comment Period from June 28 to Aug. 2, 2016
June 28, 2016


Draft Molecular Guideline Recommendations Now Open for Public Comment

Thank you for your interest in the public open comment period. The current draft recommendations are the product of an Expert Panel charged with reaffirming, updating, and revising the Molecular Testing Guideline for Selection of Lung Cancer Patients for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) published in 2013. [View Paper]

The public open comment period ends on Aug. 2, 2016. Read the news release.

All comments will be returned to the Expert Panel for consideration and evaluation. The open comment format provides opportunity for public review of both recommendation statements from the 2013 guideline that have been reaffirmed and new draft recommendations developed based upon the systematic literature review. This guideline has been developed consistent with the Institute of Medicine's Clinical Practice Guidelines You Can Trust.

Open Comment Period


CommentThe Expert Panel looks forward to receiving your comments. The Open Comment Period lasts from June 28 to Aug. 2, 2016. Thank you for your input!


The CAP/IASLC/AMP Lung Biomarkers Update Expert Panel was convened in 2015 to perform a systematic literature review and develop the practice guideline recommendations. Downloadable copies of the scope and key questions, literature search parameters, inclusion/exclusion criteria, and draft recommendations are available to download for your review.

We strongly recommend downloading and reviewing the draft recommendations prior to proceeding to the survey.

The Lung Guideline Update Draft Recommendations and literature search information provided here represent time limited information and are not to be distributed, used, or considered as an accurate representation of the CAP/IASLC/AMP Lung Guideline Update Expert Panel work product(s) after Aug. 2, 2016.

Concurrent with this open comment period, a literature refresh will be conducted and the additional findings incorporated into the final published recommendations. As such, these recommendations are to be considered in their draft form and subject to change based upon the comments gathered during this open comment period and informed by evidence gathered in the literature refresh.

The Institute of Medicine (IOM) requires evidence-based clinical practice guideline recommendation statements be reviewed and reaffirmed every five years. As part of this project, the Expert Panelists also reviewed the original 2013 practice guideline [View Paper] to determine if those published recommendation statements should be reaffirmed and updated. For consistency with current IOM practices and the new 2016 recommendation statements, the 2013 strength of recommendation language was cross-referenced with the 2016 definitions and updated.

Please click here to provide comments on these reaffirmed recommendation statements. A comparison table of the 2013 Reaffirmed and 2016 Updated draft recommendation statements and the literature search are available to download for your review.

We strongly recommend downloading and reviewing the comparison table prior to proceeding to the survey.

Thank you for contributing your time and expertise to the Lung Guideline Update Draft Recommendations development process during this open comment period. We look forward to your feedback to further enhance the final recommendations.

Open Comment Period 2016 

Project Co-Chairs:

  • Philip T. Cagle, MD on behalf of CAP
  • Yasushi Yatabe, MD, PhD on behalf of IASLC
  • Neal Lindeman, MD on behalf of AMP


About the College of American Pathologists (CAP)
As the leading organization of 18,000 board-certified pathologists, the CAP serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP's Laboratory Improvement Programs, initiated 65 years ago, currently has customers in more than 100 countries, accrediting 7,800 laboratories and providing proficiency testing to 20,000 laboratories worldwide. Find more information about the CAP at Follow the CAP on Twitter at @pathologists.

About the International Association for the Study of Lung Cancer (IASLC)
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 5,000 lung cancer specialists in over 100 countries. IASLC members promote the study of etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and thoracic malignancies. IASLC brings scientists, members of the medical community and the public together from all over the world to share best practices and discover new and better ways to eliminate the health threat of thoracic cancers. Membership is open to any physician, scientist, nurse or allied health professional interested in lung cancer and other thoracic malignancies, including patients, survivors, caregivers and advocates. Visit for more information and follow us on Twitter @IASLC.

About the Association for Molecular Pathology (AMP)
The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,300+ members include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees. Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence clinical practice, education, and policy on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing. For more information, visit and follow us on Twitter at @AMPath.